On 16 November, Pfizer Inc. announced it had reached an agreement with the Medicines Patent Pool, a United Nations-backed public health organisation, to allow the generic production of its new oral Covid-19 antiviral treatment candidate, Paxlovid, in low- and middle-income countries.
This is an important, but far too limited step forward, that should not obscure Pfizer’s record of obstructing access to its Covid-19 vaccine.